Aiko is a 35-year-old Japanese female with a 10-year history of moderate-to-severe atopic dermatitis inadequately controlled with topical corticosteroids alone. She has no significant comorbidities and no known drug allergies. Her current regimen includes daily application of medium-potency topical corticosteroids. She presents to the pharmacy seeking advice about new treatment options recently approved in Japan.

Question: Based on the ADhere-J study findings, what is the most appropriate recommendation regarding the addition of lebrikizumab to Aiko’s current treatment?

Hiroshi is a 42-year-old Japanese male recently started on lebrikizumab 250 mg every 4 weeks combined with topical corticosteroids for moderate-to-severe atopic dermatitis. He has no prior history of ocular disease. After 8 weeks of therapy, he reports mild eye redness and irritation during his follow-up visit.

Question: What is the most appropriate pharmacist counseling point regarding Hiroshi’s ocular symptoms during lebrikizumab therapy?

Emi is a 28-year-old Japanese female with moderate-to-severe atopic dermatitis who has been prescribed lebrikizumab 250 mg every 4 weeks combined with topical corticosteroids. She expresses concern about the dosing frequency and asks if more frequent dosing would improve her treatment outcomes.

Question: Based on the ADhere-J trial results, how should the pharmacist counsel Emi regarding the dosing frequency of lebrikizumab?